Session Reserved for Labcorp

Time: 3:15 pm
day: Day One


  • Cloudman S91 and YUMM1.7 melanoma models were evaluated following treatment with anti-mPD-1 and radiation therapy (RT) using flow cytometry and the NanoString® nCounter PanCancer IO 360™ panel
  • Cloudman S91 tumor growth was sensitive to checkpoint inhibition but not RT, while TUMM1.7 tumors responded only to RT
  • Treatment-induced immunophenotypic profiles and signaling pathway signatures were distinct between the two models and reflected the
    corresponding tumor growth kinetics, thus providing two unique preclinical tools for drug discovery